Molecular Diagnostics

3 May 2013
13:45 pm – 15:15 pm
GOLD Hall

# An IMPAKT 2013 Industry Satellite Symposium

**Brussels, Belgium**

# It's Time to Enable Patient Access for Molecular Diagnostics

## With Program Chairs:

Martine Piccart, MD, PhD

*Co-Chair*
*Jules Bordet Institute, Head of Chemotherapy Unit*

AND

Dr. Sherene Loi, MBBS (Hons), FRACP, PhD

*Co-Chair*
*Consultant Medical Oncologist & Group Leader*
*Translational Breast Cancer Genomics Lab*
*Peter MacCallum Cancer Centre*

Sividon Diagnostics

nanoString TECHNOLOGIES

Genomic Health™

agendia® decoding cancer.

# FACULTY


### Martine Piccart, MD, PhD
Co-Chair
Jules Bordet Institute, Head of Chemotherapy Unit
IMPAKT Co-Founder
Brussels, Belgium

### Dr. Sherene Loi, MBBS (Hons), FRACP, PhD
Co-Chair
Consultant Medical Oncologist & Group Leader
Translational Breast Cancer Genomics Lab
Peter MacCallum Cancer Centre
East Melbourne, Victoria Australia

### Miguel Martin, MD, PhD
Medical Oncology Department
Clínico San Carlos Hospital, Madrid
President, GEICAM
Madrid, Spain

### Frederique Penault-Llorca, MD, PhD
Department of Pathology
Centre Jean-Perrin
Clermont-Ferrand, France

### Adrian Towse MA MPhil
Director of the Office of Heath Economics
London, UK

### Eva Schumacher-Wulf
Editor in Chief
Mamma MIA – The Breast Cancer Magazine
Kronberg, Germany


Innovative

# AGENDA

## FRIDAY, 3 MAY 2013

| | |
|---|---|
| 13:45 PM | It's Time to Enable Patient Access for Well-validated Molecular Diagnostics * Martine Piccart |
| 13:55 PM | Evidence Supporting the Use of RNA-based Tests to Stratify Breast Cancer Patients – Are They All the Same? * Miguel Martin |
| 14:15 PM | How Can We Ensure Quality and Safety for Biomarkers Used in Breast Cancer? * Frederique Penault-Llorca |
| 14:30 PM | Evaluating Cost Effectiveness of Molecular Diagnostics * Adrian Towse |
| 14:45 PM | Ensuring Equity for Patients * Eva Schumacher-Wulf |
| 14:55 PM | Panel Discussion and Summary * Martine Piccart and Sherene Loi Panelists: Miguel Martin, Frederique Penault-Llorca, Adrian Towse, Eva Schumacher-Wulf, Iain Miller (EPEMED), and David Byrne (EAPM) |

# PROGRAM DESCRIPTION

The emergence of innovative molecular diagnostics is changing the diagnosis and treatment of cancer. Molecular tools have the potential to better identify which patients may benefit from a particular therapy and which treatments can be avoided. While the tools are offering more robust information in personalizing cancer treatments, but due to lack of reimbursement they are not readily available to many European patients. Most commercially available molecular diagnostic tests today are for early stage breast cancer, but increasingly there will be new tests across the continuum of the disease. Clinicians need to be well versed in evaluating which tests should be used in the clinic and recommended by healthcare systems for reimbursement. This session will discuss how to evaluate molecular diagnostics in breast cancer relative to existing markers for treatment decisions.

# SYMPOSIUM OBJECTIVE

To establish an appropriate framework for participants to introduce molecular diagnostics for reimbursement in their healthcare system.

Molecular Diagnostics

IMPAKT